A small Seattle biotech wants to take on GlaxoSmithKline's emerging Shingrix blockbuster. RA Capital is on board

Max Gelman

Senior Editor

GlaxoSmithKline’s Shingrix has quickly become one of the company’s best-selling products since first winning FDA approval in 2017. But a new biotech believes it can …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A small Seattle biotech wants to take on GlaxoSmithKline's emerging Shingrix blockbuster. RA Capital is on board

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

A small Seat­tle biotech wants to take on Glax­o­SmithK­line's emerg­ing Shin­grix block­buster. RA Cap­i­tal is on board

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

A small Seattle biotech wants to take on GlaxoSmithKline's emerging Shingrix blockbuster. RA Capital is on board